» Articles » PMID: 18237690

Combined Metabolomic and Proteomic Analysis of Human Atrial Fibrillation

Abstract

Objectives: We sought to decipher metabolic processes servicing the increased energy demand during persistent atrial fibrillation (AF) and to ascertain whether metabolic derangements might instigate this arrhythmia.

Background: Whereas electrical, structural, and contractile remodeling processes are well-recognized contributors to the self-perpetuating nature of AF, the impact of cardiac metabolism upon the persistence/initiation of this resilient arrhythmia has not been explored in detail.

Methods: Human atrial appendage tissues from matched cohorts in sinus rhythm (SR), from those who developed AF post-operatively, and from patients in persistent AF undergoing cardiac surgery were analyzed using a combined metabolomic and proteomic approach.

Results: High-resolution proton nuclear magnetic resonance (NMR) spectroscopy of cardiac tissue from patients in persistent AF revealed a rise in beta-hydroxybutyrate, the major substrate in ketone body metabolism, along with an increase in ketogenic amino acids and glycine. These metabolomic findings were substantiated by proteomic experiments demonstrating differential expression of 3-oxoacid transferase, the key enzyme for ketolytic energy production. Notably, compared with the SR cohort, the group susceptible to post-operative AF showed a discordant regulation of energy metabolites. Combined principal component and linear discriminant analyses of metabolic profiles from proton NMR spectroscopy correctly classified more than 80% of patients at risk of AF at the time of coronary artery bypass grafting.

Conclusions: The present study characterized the metabolic adaptation to persistent AF, unraveling a potential role for ketone bodies, and demonstrated that discordant metabolic alterations are evident in individuals susceptible to post-operative AF.

Citing Articles

Partial Regulation of Ketone Metabolism by Hypoxia in H9C2 Cardiomyocytes.

Chen L, Chen H, Zhang X, Ling S, Xu J Curr Med Sci. 2025; 45(1):25-34.

PMID: 39976748 DOI: 10.1007/s11596-025-00002-w.


Relaxin-2 Exhibits a Beneficial Role in Energy Metabolism to Alleviate Atrial Fibrillation Susceptibility.

Zhao X, Cao Y, Gao Q, Han X, Zhang H, Mu H ACS Pharmacol Transl Sci. 2025; 8(2):368-379.

PMID: 39974648 PMC: 11833732. DOI: 10.1021/acsptsci.4c00354.


Metabolomics in Atrial Fibrillation: Unlocking Novel Biomarkers and Pathways for Diagnosis, Prognosis, and Personalized Treatment.

Rohun J, Dudzik D, Raczak-Gutknecht J, Wabich E, Mlodzinski K, J Markuszewski M J Clin Med. 2025; 14(1.

PMID: 39797116 PMC: 11722095. DOI: 10.3390/jcm14010034.


Integrated untargeted/targeted metabolomics identifies a putative oxylipin signature in patients with atrial fibrillation and coronary heart disease.

Li L, Lu Y, Du Z, Fang M, Wei Y, Zhang W J Transl Int Med. 2024; 12(5):495-509.

PMID: 39513034 PMC: 11538890. DOI: 10.1515/jtim-2023-0141.


Underlying mechanisms of ketotherapy in heart failure: current evidence for clinical implementations.

Liu K, Yang Y, Yang J Front Pharmacol. 2024; 15:1463381.

PMID: 39512825 PMC: 11540999. DOI: 10.3389/fphar.2024.1463381.